Table 3 Clinicopathological characteristics of LUSC patients(n = 70).

From: Low expression of SGCA promotes lung squamous cell carcinoma malignant progression

Characteristics

Low expression of SGCA

High expression of SGCA

P value

n

52

18

 

Gender, n (%)

  

0.764

 Female

8 (11.4%)

4 (5.7%)

 

 Male

44 (62.9%)

14 (20%)

 

Age, mean ± SD

68.019 ± 6.5334

67.667 ± 7.3485

0.849

Pathologic T stage, n (%)

  

< 0.001

 1

18 (25.7%)

17 (24.3%)

 

 2

25 (35.7%)

1 (1.4%)

 

 3

6 (8.6%)

0 (0%)

 

 4

3 (4.3%)

0 (0%)

 

Pathologic N stage, n (%)

  

0.218

 0

37 (52.9%)

17 (24.3%)

 

 1

7 (10%)

1 (1.4%)

 

 2

5 (7.1%)

0 (0%)

 

 3

3 (4.3%)

0 (0%)

 

Pathologic M stage, n (%)

  

0.714

 1

3 (4.3%)

0 (0%)

 

 0

49 (70%)

18 (25.7%)

 

Pathologic Stage, n (%)

  

0.020

 1

28 (40%)

17 (24.3%)

 

 3

11 (15.7%)

0 (0%)

 

 2

10 (14.3%)

1 (1.4%)

 

 4

3 (4.3%)

0 (0%)

 

Number pack years smoked, median (IQR)

20 (3.75, 40)

12.5 (0, 35)

0.225

 CEA (ng/ml), median (IQR)

3.64 (2.35, 6.03)

3.09 (2.43, 4.71)

0.676

 CYFRA21-1 (ng/ml), median (IQR)

2.61 (1.665, 4.805)

1.4 (0.86, 1.7025)

< 0.001

 SCC (ng/ml), median (IQR)

0.95 (0.7, 1.525)

1 (0.9, 1.2)

0.912

 NSE (ng/ml), median (IQR)

4.05 (3.18, 5.145)

3.69 (3.3175, 4.335)

0.600

 Blood Ca2+(mmol/l), median (IQR)

2.235 (2.1875, 2.3325)

2.26 (2.175, 2.345)

0.971

 Lesion CT value Max, median (IQR)

73.5 (49.75, 93.5)

81.5 (54.75, 89.5)

0.877

 Lesion CT value Min, median (IQR)

10.5 (-10.5, 23.25)

-13 (-24.5, 13.5)

0.148

 Mean lesion CT value, mean ± SD

41.654 ± 19.211

30.222 ± 24.967

0.048

 Cystatin C (mg/L), median (IQR)

0.88 (0.76, 1)

0.8 (0.75, 0.94)

0.307

 Creatinine (umol/L), median (IQR)

69.15 (62.75, 81.075)

43.99 (37.367, 59.145)

< 0.001

 Uric Acid (umol/L), median (IQR)

301.5 (247, 356.25)

305.5 (270.75, 327.5)

0.830

 LDH (u/l), median (IQR)

178.5 (161.75, 208.75)

178.5 (149.75, 202.25)

0.619

  1. Bold values denote p < 0.05.